Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice

Chemotherapy

Volumn 49, Issue 3, 2003, Pages 126-131

  Smee, Donald F ^a   Bailey, Kevin W ^a   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral treatment; Cidofovir; Cowpox virus; Cyclic HPMPC; Vaccinia virus

Indexed keywords

1 [(2 HYDROXY 2 OXO 1,4,2 DIOXAPHOSPHORINAN 5 YL)METHYL]CYTOSINE; ANTIVIRUS AGENT; CIDOFOVIR; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; VACCINIA; VACCINIA VIRUS; VIRUS LOAD;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; COWPOX; CYTOSINE; FEMALE; INFUSIONS, PARENTERAL; LIVER; LUNG DISEASES; MICE; MICE, INBRED BALB C; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; VACCINIA;

EID: 0037632802     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070618     Document Type: Article

References (25)

1. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW: Cidofovir (HPMPC) protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000;181:10-19.
2. Smee DF, Bailey KW, Sidwell RW: Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem Chemother 2001;12:71-76.
3. Smee DF, Bailey KW, Wong M-H, Sidwell RW: Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 2001;52:55-62.
4. De Clercq E: Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55:1-13.
5. Breman JG, Henderson DA: Poxvirus dilemmas - monkeypox, smallpox and biological terrorism. N Engl J Med 1998;339:556-559.
6. Hooper C: Poxvirus dilemmas. N Engl J Med 1998;339:2027-2028.
7. Orent W: Excape from Moscow. Sciences (New York) 1998;38:26-31.
8. Peters CJ: Many viruses are potential agents of bioterrorism. ASM News 2002;68:168-173.
9. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL: Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997;25:911-914.
10. Meadows KP, Tyring SK, Pavia AT, Rallis TM: Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997;133:987-990.
11. Davies EG, Thrasher A, Lacey K, Harper J: Topical cidofovir for severe molluscum contagiosum. Lancet 1999;353:2042.
12. Ibarra V, Blanco JR, Oteo JA, Rosel L: Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol 2000;80:315-316.
13. Toro JR, Wood LV, Patel NK, Turner ML: Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000;136:983-985.
14. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, Degreef H, Maes B: A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 2001;64:543-549.
15. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, Lietman PS: Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 1996;29:153-161.
16. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E: HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997;8:1-23.
17. Bischofberger N, Hitchcock MJM, Chen MS, Barkhimer DB, Cundy KC, Kent KM, Lacy SA, Lee WA, Li Z-H, Mendel DB, Smee DF, Smith JL: 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1,(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38:2387-2391.
18. Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA: Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos 1996;24:745-752.
19. Bourne N, Bravo FJ, Bernstein DI: Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral Res 2000;47:103-109.
20. Cundy KC, Barditch-Crovo P, Petty BG, Ruby A, Redpath M, Jaffe HS, Lietman PS: Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43: 271-277.
21. Oliyai R, Arimilli MN, Jones RJ, Lee WA: Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleoside Nucleotides Nucleic Acids 2001;20:1411-1414.
22. Bray M, Martinez M, Kefauver D, West M, Roy C: Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 2002;54:129-142.
23. Smee DF, Bailey KW, Wong M-H, Sidwell RW: Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res 2000;47:171-177.
24. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong M-H, Morrison A, Syndergaard T, Kim CU: Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998;37:107-120.
25. Smee DF, Bray M, Huggins JW: Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chem Chemother 2002;12:327-335.